Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT06837896

Efficacy and Safety Study of QLG1080 in Patients With Hormone-sensitive Advanced Prostate Cancer

A Multicenter Study Evaluating the Efficacy and Safety of QLG1080 in Patients With Hormone-sensitive Advanced Prostate Cancer

Status
Not Yet Recruiting
Phase
Phase 3
Study type
Interventional
Enrollment
110 (estimated)
Sponsor
Qilu Pharmaceutical Co., Ltd. · Industry
Sex
Male
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study was to evaluate the efficacy and safety of QLG1080 in patients with hormone-sensitive advanced prostate cancer.

Conditions

Interventions

TypeNameDescription
DRUGQLG1080Oral administration

Timeline

Start date
2025-02-01
Primary completion
2026-11-01
Completion
2026-12-01
First posted
2025-02-20
Last updated
2025-02-20

Source: ClinicalTrials.gov record NCT06837896. Inclusion in this directory is not an endorsement.

Efficacy and Safety Study of QLG1080 in Patients With Hormone-sensitive Advanced Prostate Cancer (NCT06837896) · Clinical Trials Directory